Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 10/20 | 0.69 |
| ▸ | NPY4R | P50391 | 8/20 | 0.69 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.69 |
| ▸ | NPY1R | P25929 | 8/20 | 0.69 |
| ▸ | CALCR | P30988 | 4/20 | 0.64 |
| ▸ | EP300 | Q09472 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | TFPI | P10646 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sstcipsgqpcpynenccsqsctykenengntvkrcd SCHEMBL29838759 | 0.98 | NPY2R (0.67) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| Sptcipsgqpcpynenccsqsctfkenengntvkrcd SCHEMBL29695388 | 0.95 | NPY2R (0.65) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30712939 | 0.93 | EP300 (0.67) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30658265 | 0.92 | NPY2R (0.70) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| Cipsgqpcpynenccsqsctfkenengntvkrcd SCHEMBL29993310 | 0.92 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30432502 | 0.91 | NPY2R (0.67) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31182982 | 0.91 | NPY2R (0.73) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL8814395 | 0.91 | NPY2R (0.71) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30658298 | 0.91 | NPY2R (0.71) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31182925 | 0.90 | CALCR (0.68) | NPY2RNPY4RNPY5RNPY1RCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042807-A1 | NEXT GENERATION ACTX PEPTIDES | Vestaron Corporation (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250115647-A1 | HV1 MODULATORS AND USES | UNIV CALIFORNIA (US) | 2025-04-10 | — | — | US | disclosed |
| US-12084481-B2 | HV1 modulators and uses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240076327-A1 | PESTICIDAL HEXATOXIN POLYPEPTIDES AND METHODS OF USE THEREOF | SYNGENTA CROP PROTECTION AG (CH) | 2024-03-07 | — | — | US | disclosed |
| US-20220289800-A1 | HV1 MODULATORS AND USES | UNIV CALIFORNIA (US) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042807-A1 | NEXT GENERATION ACTX PEPTIDES | CRYAA, RNGTT, CALML3 | NPY2R 3324/4885NPY4R 3338/4885NPY5R 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.